Gusev Catalyst for Ester Hydrogenation
Johnson Matthey has manufactured a new Gusev catalyst for ester hydrogenation using technology that promotes sustainability and improved reactivity and selectivity, according to the company.
Johnson Matthey (JM), a provider of pharmaceutical services, active pharmaceutical ingredients, and catalyst technologies, has added a new Gusev catalyst for ester hydrogenation to its product offerings.
The catalyst, Ru-SNS, uses licensed technology conceived and developed in the laboratories of Professor Dmitri Gusev of Wilfrid Laurier University in Waterloo, Ontario, Canada, and licensed to JM in 2016 by GreenCentre Canada, a provider of intellectual property services to support the development of chemistry-driven activities. The catalyst combines high activity with high chemoselectivity, providing improvements for industrial applications of ester hydrogenation. The catalyst also possesses a higher tolerance of challenging functional groups, according to the company.
The company also reports that reactions using this catalyst are safer compared to existing industrial processes, owing to the milder operating conditions, and produce less environmental waste, providing economic and environmental performance improvement for various large-scale commercial chemical processes.
Source: Johnson Matthey
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
